Ariel Jones

Articles by Ariel Jones

Ariel JonesCancer | December 28, 2021
Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, showed promising efficacy in patients with ...
Read More
Ariel JonesCancer | December 28, 2021
A fixed-duration combination of the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the ...
Ariel JonesCancer | December 28, 2021
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as ...
Ariel JonesMultiple Myeloma | December 28, 2021
The trial was conducted by Dr. Malin Hultcrantz and colleagues, and presented at the 2021 American Society of Hematology.
Ariel JonesCancer | December 23, 2021
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
Ariel JonesCancer | December 23, 2021
The all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable MRD ...
Ariel JonesMultiple Myeloma | December 23, 2021
In the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study, researchers explored whether ...
Ariel JonesMultiple Myeloma | December 23, 2021
These results were presented at the 2021 American Society of Hematology Annual Meeting.
Ariel JonesCancer | June 11, 2021
A study presented during the 2021 ASCO Annual Meeting observed a significant correlation between race and being harmed ...